Jung I - Search Results

1

Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.

Youn JI, Park SM, Park S, Kim G, Lee HJ, Son J, Hong MH, Ghaderpour A, Baik B, Islam J, Choi JW, Lee EY, Kim HR, Seo SU, Paik S, Yoon HI, Jung I, Xin CF, Jin HT, Cho BC, Seong SY, Ha SJ, Kim HR. Youn JI, et al. Among authors: jung i. Sci Rep. 2020 Jun 3;10(1):9050. doi: 10.1038/s41598-020-65666-x. Sci Rep. 2020. PMID: 32493990 Free PMC article.

2

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: jung i. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.

3

The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.

Park JS, Lee JS, Kim EY, Jung JY, Kim SK, Chang J, Kim DJ, Lee CY, Jung I, Kim JH, Kim HR, Moon YW, Kim HS, Cho BC, Shim HS. Park JS, et al. Among authors: jung jy, jung i. Lung Cancer. 2015 Jun;88(3):325-31. doi: 10.1016/j.lungcan.2015.03.002. Epub 2015 Mar 9. Lung Cancer. 2015. PMID: 25819384

4

A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.

Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, Kim HR, Cho BC. Heo SJ, et al. Among authors: jung i. Cancer Chemother Pharmacol. 2016 Mar;77(3):539-48. doi: 10.1007/s00280-016-2968-z. Epub 2016 Jan 25. Cancer Chemother Pharmacol. 2016. PMID: 26811178 Clinical Trial.

5

The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma.

Yoon HI, Jung I, Han KH, Seong J. Yoon HI, et al. Among authors: jung i. Oncotarget. 2016 Sep 20;7(38):62715-62725. doi: 10.18632/oncotarget.10908. Oncotarget. 2016. PMID: 27486881 Free PMC article.

6

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).

Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC. Kim HR, et al. Among authors: jung i. Oncotarget. 2017 Feb 28;8(9):15943-15951. doi: 10.18632/oncotarget.13056. Oncotarget. 2017. PMID: 27823977 Free PMC article. Clinical Trial.

7

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.

Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC, Yoon SO. Kim HR, et al. Among authors: jung i. Sci Rep. 2016 Nov 14;6:36956. doi: 10.1038/srep36956. Sci Rep. 2016. PMID: 27841362 Free PMC article.

8

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).

Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC. Kim HR, et al. Among authors: jung i. Oncotarget. 2017 Aug 14;8(33):55766. doi: 10.18632/oncotarget.20268. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903459 Free PMC article.

9

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.

Kim HR, Cha YJ, Hong MH, Gandhi M, Levinson S, Jung I, Lee JG, Lee CY, Cho BC, Ha SJ, Shim HS. Kim HR, et al. Among authors: jung i. Oncotarget. 2017 Aug 14;8(50):87234-87243. doi: 10.18632/oncotarget.20254. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152077 Free PMC article.

10

The Ratio of Peripheral Regulatory T Cells to Lox-1⁺ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.

Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI. Kim HR, et al. Among authors: jung i. Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE. Am J Respir Crit Care Med. 2019. PMID: 30339766 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,664 results

Search Page